Morgan Stanley’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,831
| Closed | -$396 | – | 8016 |
|
|
2024
Q1 | $396 | Sell |
2,831
-2,834
| -50% | -$558 | ﹤0.01% | 7261 |
|
|
2023
Q4 | $824 | Buy |
5,665
+2,831
| +100% | +$440 | ﹤0.01% | 7227 |
|
|
2023
Q3 | $497 | Sell |
2,834
-3,512
| -55% | -$4.36K | ﹤0.01% | 7307 |
|
|
2023
Q2 | $19.8K | Sell |
6,346
-50,789
| -89% | -$151K | ﹤0.01% | 6574 |
|
|
2023
Q1 | $146K | Buy |
57,135
+56,744
| +14,513% | +$117K | ﹤0.01% | 5845 |
|
|
2022
Q4 | $582 | Sell |
391
-691
| -64% | -$1.12K | ﹤0.01% | 7539 |
|
|
2022
Q3 | $2K | Sell |
1,082
-3,025
| -74% | -$4.28K | ﹤0.01% | 7504 |
|
|
2022
Q2 | $6K | Sell |
4,107
-1,441
| -26% | -$2.47K | ﹤0.01% | 7374 |
|
|
2022
Q1 | $13K | Sell |
5,548
-184,968
| -97% | -$482K | ﹤0.01% | 7323 |
|
|
2021
Q4 | $874K | Buy |
190,516
+184,908
| +3,297% | +$611K | ﹤0.01% | 5169 |
|
|
2021
Q3 | $45K | Sell |
5,608
-293
| -5% | -$2.51K | ﹤0.01% | 6774 |
|
|
2021
Q2 | $57K | Sell |
5,901
-6,406
| -52% | -$52K | ﹤0.01% | 6617 |
|
|
2021
Q1 | $108K | Sell |
12,307
-3,680
| -23% | -$40.4K | ﹤0.01% | 5967 |
|
|
2020
Q4 | $164K | Buy |
15,987
+13,210
| +476% | +$144K | ﹤0.01% | 5686 |
|
|
2020
Q3 | $25K | Sell |
2,777
-3,016
| -52% | -$23.9K | ﹤0.01% | 5983 |
|
|
2020
Q2 | $41K | Buy |
5,793
+1,046
| +22% | +$11.1K | ﹤0.01% | 5747 |
|
|
2020
Q1 | $45K | Buy |
4,747
+2,391
| +101% | +$30.8K | ﹤0.01% | 5504 |
|
|
2019
Q4 | $31K | Buy |
+2,356
| New | +$28.7K | ﹤0.01% | 5992 |
|
Other funds holding GRTX
Morgan Stanley's GRTX Position: Q2 2024 in Review
Morgan Stanley sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 2,831 shares — an estimated $396 sold.
Morgan Stanley first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $874K in Q4 2021. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- Morgan Stanley reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 2,831 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $396.
- Morgan Stanley first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Morgan Stanley's Galera Therapeutics, Inc. Common Stock position peaked at $874K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.